You are here

Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
University Hospital of Alexandroupolis Dimokritio
Alexandroupolis, Thrace, 68100 Greece
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of Alzheimer's Disease

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- There are no exclusion criteria

NCT01089582
Pfizer
Completed
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets
Quality Of Life Assessment In AD Patients Receiving Aricept Tablets (Donepezil Hydrochloride)
This study assessed the Hr QoL (Health related Quality of life) of subjects with mild to moderate AD, who received ARICEPT under usual clinical practice.
This non-interventional study enrolled patients with mild to moderate dementia of the Alzheimer's type, who have been prescribed treatment with ARICEPT under usual clinical practice.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients with mild to moderate dementia of the Alzheimer's type
Alzheimer Disease
Other: No intervention
AD patients
Intervention: Other: No intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
628
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of Alzheimer's Disease

Exclusion Criteria:

  • There are no exclusion criteria
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Greece
 
 
NCT01089582
A2501054
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now